SCHEMBL19686630

SCHEMBL19686630

Cc1cc(NC2CCC(F)(F)CC2)nc(-n2cc(C)c(CF)n2)n1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNN2 Q9H2S1 1/20 0.45
KCNN3 Q9UGI6 1/20 0.45
IDH1 O75874 10/20 0.41
IDH2 P48735 2/20 0.41
LMNA P02545 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
ALOX15 P16050 1/20 0.31
KIF18A Q8NI77 2/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
POLB P06746 1/20 0.31
PDE2A O00408 1/20 0.31
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19686316 0.91 KCNN2 (0.44) KCNN2KCNN3IDH1IDH2LMNA
SCHEMBL19686957 0.84 KCNN2 (0.43) KCNN2KCNN3IDH1IDH2KIF18A
SCHEMBL19687234 0.84 ADORA2A (0.39) IDH1IDH2LMNAHTTSMN1; SMN2
SCHEMBL19687401 0.83 IDH1 (0.37) KCNN2KCNN3IDH1IDH2
SCHEMBL19686619 0.82 KCNN2 (0.42) KCNN2KCNN3IDH1IDH2KIF18A
SCHEMBL21143751 0.82 KCNN2 (0.42) KCNN2KCNN3IDH1IDH2KIF18A
SCHEMBL21143864 0.81 KCNN2 (0.41) KCNN2KCNN3IDH1IDH2KIF18A
SCHEMBL19687485 0.81 IDH1 (0.42) KCNN2KCNN3IDH1IDH2
SCHEMBL19687320 0.81 IDH1 (0.47) KCNN2KCNN3IDH1IDH2LMNA
SCHEMBL21143790 0.81 KCNN2 (0.40) KCNN2KCNN3IDH1IDH2KIF18A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885IDH1 3017/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885IDH1 3017/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885IDH1 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.